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1250Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC) in
Elderly Patients: Results of a Treatment Algorithm
Employing Allogeneic Stem Cell Transplantation with
Moderately Reduced Conditioning Intensity
Sascha Dietrich,1 Mindaugas Andrulis,2 Ute Hegenbart,1 Thomas Schmitt,1 Frauke Bellos,1
Uwe M. Martens,3 Julia Meissner,1 Alwin Kr€amer,1 Anthony D. Ho,1 Peter Dreger1Blastic plasmacytoid dendritic cell neoplasm (BPDC), formerly known as blastic NK cell lymphoma, is a rare
hematopoietic malignancy preferentially involving skin, bone marrow, and lymph nodes. The overall progno-
sis of BPDC is dismal, with a median overall survival (OS) of only 12 to 14 months despite aggressive che-
motherapy. Anecdotal reports suggest that younger patients might benefit from myeloablative therapy
with autologous or allogeneic stem cell transplantation (alloSCT). However, with a median age at diagnosis
beyond 60 years, BPDC primarily affects elderly patients. Here, we present for the first time evidence that
also in elderly patients, alloSCT for BPDC is feasible andmay result in sustained remission if conditioning with
moderately reduced intensity is used. Between 2006 and 2009, 6 patients were treated at our institution who
fulfilled the diagnostic criteria for BPDC. Median age was 67 (range: 55-80) years. All responded to acute
leukemia-type induction therapy. Whereas 2 patients who were ineligible for alloSCTrapidly died of disease
recurrence, 4 patients underwent alloSCT from unrelated donors as part of first-line (n5 1) or salvage treat-
ment (n5 3). Two patients allografted in remission live disease free 57 and 16 months post-alloSCT, whereas
2 patients transplanted with active disease achieved complete remission but relapsed 6 and 18 months after
transplantation, respectively. In conclusion, reduced-intensity conditioning (RIC) alloSCT from unrelated
donors is feasible and seems to be effective in elderly patients with BPDC, suggesting that alloSCT should
be pursued aggressively in patients with this otherwise fatal disease up to 70 years of age.
Biol Blood Marrow Transplant 17: 1250-1254 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: Blastic plasmacytoid dendritic cell neoplasm, BPDCN, Allogeneic stem cell transplantationINTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm
(BPDC) is a rare hematopoietic neoplasia preferen-
tially involving the skin, the bone marrow, and lymph
nodes. Although the typical CD41/CD561 expression
of this tumor resulted in provisional classification as
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6/j.bbmt.2010.12.706lar, and functional properties, such as CD123, TCL1
expression, and production of interferon-alpha
(IFN-a), suggested pathogenetic relations to plasma-
cytoid dendritic cells, paving the way for the term
‘‘Blastic plasmacytoid dendritic cell neoplasm,’’ which
now has been adopted by the 2008WHOclassification
[1-3]. The putative normal counterpart of BPDC is the
precursor of the plasmacytoid dendritic cells [3].
BPDC has a male/female ratio of 3:1 and primarily
affects elderly patients (median age at diagnosis 60-70
years) but has occurred in patients younger than
40 years in 20% to 30% of the cases [4,5]. Up to
90% of patients have skin lesions. Lymph node
involvement is common (40%-50%), and low-level
bone marrow and peripheral blood involvement are
seen in most cases (60%-90%); however, initial fulmi-
nant leukemia is rare (5%-25%). Overt leukemia is
a common feature of BPDC progression or relapse, of-
ten with a myelomonocytic phenotype, and is nearly
always present in the terminal stage. The overall prog-
nosis for patients with BPDC is dismal, with a median
Biol Blood Marrow Transplant 17:1250-1254, 2011 1251BPDC in Elderly Patientsoverall survival of 12 to 14 months, irrespective of the
initial pattern of disease [4,5]. Most cases show an
initial response to multiagent chemotherapy (80%-
90%), but relapses with subsequent drug resistance
occur in the vast majority of patients after a median of
only 9 to 11 months [5-7]. However, superior results
have been reported anecdotally in younger patients
who received stem cell transplantation (SCT). These
very preliminary reports suggest that long-term disease
control can be achieved by myeloablative treatment
followed by autologous or allogeneic SCT (alloSCT)
in selected young patients transplanted in first remis-
sion [5,7].
Here,wepresent for thefirst time evidence that also
in elderly patients alloSCT is feasible andmay result in
sustained remission of BPDC if conditioning with
moderately reduced intensity is used. This is also the
first report showing that alloSCT in BPDC can be suc-
cessful without the use of total-body irradiation (TBI),
and that it can be safely performed with well-matched,
partially matched, or mismatched unrelated donors.PATIENTS AND METHODS
Identification of Patients
The electronic patient file system of the institution
was screened for all patients with BPDC treated
between 2006 and 2009 using the terms ‘‘blastic plas-
macytoid dendritic cell neoplasm’’ and ‘‘blastic NK
lymphoma.’’ For verification of the diagnosis of
BPDC, tissue sections or the written histology and im-
munophenotyping reports were reviewed by an experi-
enced hematopathologist (M.A.), and the diagnostic
algorithm suggested by Tsagarakis et al. [8] and
Garnache-Ottou et al. [9] was applied. Coexpression
of CD4, CD56, andCD123 in the absence of other lin-
eage specific markers such as CD11c, MPO, lysozyme,
CD79a, cCD3was theminimum requirement for diag-
nosis.
Treatment Policy
Because of the paucity of published information
and in the absence of a formal protocol for this orphan
disease, no stringent treatment policy was in place.
However, basically, the treatment algorithm employed
was as follows: if not precluded by comorbidity or very
advanced age, patients received an acute leukemia-like
induction regimen consisting of daunorubicin and
cytarabine (Ara-C) followed by high-dose Ara-C
consolidation or equivalent (AML-like; 3 patients),
or containing dexamethasone, methotrexate, vincris-
tine, cyclophosphamide, adriamycin/daunorubicin,
cyclophosphamide/ifosfamide (ALL-like; 3 patients).
Once relapse occurred, patients received individual
salvage therapy followed by reduced-intensity condi-
tioning (RIC) alloSCT in responding patients youngerthan 70 years with a comorbidity score (HCT-CI) of
equal or less than 2 [10]. From 2009 onward, it was in-
tended to perform consolidating RIC alloSCT as part
of first-line therapy.
Patients were treated according to protocols ap-
proved by the responsible institutional review board
and gave written informed consent to each individual
treatment.
alloSCT
Conditioning was selected according to the co-
morbidity of the individual patient. Because the disease
was considered as blastic NK cell lymphoma until 2008,
however, attempts were made to treat the patients on
a protocol that was in place for alloSCT of poor-risk
aggressive lymphoma at our institution (DSHNHL
2003 R3, BfArM Nr. 4021777). This protocol used
submyeloablative doses of busulfan with fludarabine
and cyclophosphamide, followed by transplantation
of unmanipulated peripheral blood stem cell grafts
obtained from siblings or unrelated donors [11]. If
age or comorbidity precluded the use of this regimen,
fludarabine-treosulfan was used instead [12]. Patients
with an unrelated donor received anti-thymocyte
globuline (ATG). Unrelated donors were selected
according to the results of high-resolution HLA geno-
typing for HLA-A, -B, -C, -DRB1, and -DQB1) [13].
Unrelated donor matching was classified as well-
matched, partially matched, or mismatched according
to the proposal by Weisdorf et al. [14]. Posttransplant
immunosuppression was performed with cyclosporine
andmethotrexate ormycophenolate mofetil and tacro-
limus. Supportive care was applied according to local
standard operating procedures.RESULTS
Patient Characteristics at Diagnosis
Nine patients who matched the search criteria
could be identified from our databases. According to
the diagnostic algorithm suggested by Garnache-
Ottou et al. [9] and Tsagarakis et al. [8], the diagnosis
of BPDC had to be rejected in 2 patients because of
a moderate lysozyme expression in their blasts, despite
a strong coexpression of CD4, CD56, CD123, and
a typical clinical presentation with multiple skin le-
sions during the first diagnosis. For another patient,
CD123, BDCA-2, or BDCA-4 staining has not been
available and was therefore not considered to have
proven BPDC. Characteristics of the remaining 6 pa-
tients in whom the diagnosis of BPDC could be con-
firmed are shown in Table 1. Median age at
diagnosis was 67 (range: 55-80) years. At initial presen-
tation, all patients had multiple skin lesions, 4 patients
had bone marrow involvement, and only 1 patient had
BPDC-specific blasts detectable in the peripheral
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1252 Biol Blood Marrow Transplant 17:1250-1254, 2011S. Dietrich et al.blood. Four patients had lymph node enlargement,
which was biopsied in 2 patients, confirming the diag-
nosis of BPDC.
First-Line Treatment
All patients responded very well to the induction
chemotherapy (complete remission [CR]: n 5 5/6,
partial remission [PR]: n 5 1/6). However, 5 out of 6
patients relapsed after a median of 7 months (range:
3-11 months) after start of induction treatment. The
only patient (#6) who did not experience disease recur-
rence underwent alloSCT in first CR and maintained
the CR ever since (19 months) (Table 1).
Relapse Treatment and alloSCT
Because of advanced age and comorbidity, 2 pa-
tients (#3 and #4) were ineligible for further treatment
intensification and therefore did not undergo alloSCT.
Both of them died very rapidly because of disease pro-
gression.The 3 remainingpatientswho experienced re-
lapse after frontline treatment proceeded to alloSCT
(Table 2): patient #1 responded to high-dose metho-
trexate (8 g/m2) given as salvage treatment andwas sub-
sequently allografted from a mismatched unrelated
donor. He is enjoying ongoing CR for more than 57
months after alloSCT. Patient #2 did not respond to
a variety of salvage attempts and underwent alloSCT
with refractory disease. He achieved a CR directly after
alloSCT but relapsed 6 months thereafter and subse-
quently died of progressive disease. Patient #5 showed
skin relapse 3 months after induction treatment and
proceeded without any salvage attempt to the planned
alloSCT, which resulted in a prompt CR. After a
very uneventful course, he experienced rapid prolifera-
tion of blood and marrow BPDC blasts 18 months
posttransplant.DISCUSSION
BPDC is an aggressive hematopoietic neoplasm
with a very poor prognosis. So far, only little is known
on how to achieve durable responses in BPDC. Re-
imer et al. [5] reviewed the literature on treatment
of BPDC in 2003 and found 91 cases, virtually all
published as individual case reports. Whereas in 66
patients, initial treatment consisted of local therapy
or CHOP-like therapy only (CR rate 55%-70%),
17 received acute-leukemia–like induction treatment
(CR rate 94%). The remaining 10 patients had
been treated in first or subsequent CR with myeloa-
blative therapy followed by alloSCT in 6 patients
and by autologous stem cell transplantation
(autoSCT) in 4 patients. Whereas only 1 of the 4
autoSCT patients enjoyed long-term remission, 3
out of 4 patients who received allografts in first CR
remained alive and disease free 98 (76-115) months
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Biol Blood Marrow Transplant 17:1250-1254, 2011 1253BPDC in Elderly Patientsposttransplant. It has to be stressed that the median
age of these 4 patients was only 26 (6-29) years. In
contrast, median overall survival (OS) was only 9 to
13 months in the other 3 groups without alloSCT
consolidation. Age emerged as significant prognostic
factor (OS 18 months for patients \60 years versus
9 months for patients .60 years; P\ .0001). Taking
into account the limitations inferred by the heteroge-
neity and the retrospective nature of this compilation,
these results suggested that a proportion of younger
patients might be cured with high-dose therapy fol-
lowed by alloSCT or autoSCT performed in first
complete remission.
A registry analysis from the French Cutaneous
Lymphoma database described 47 patients with
BPDC [7]. Thirty-seven were treated with radiation,
monochemotherapy, or polychemotherapy only,
whereas 10 received an additional autoSCT (n 5 1)
or alloSCT (n5 9). The median age of the allografted
patients was 38 years. In the absence of any further
information on donor source, conditioning, and other
essential transplant-related variables, OS of the trans-
planted patients was 40 months and thus significantly
better than that of the 37 nontransplanted patients
who had a median survival of 1 year [7]. Similarly,
a case collection by Bekkenk et al. [4] found superior
outcome of 8 patients who underwent autologous or
allogeneic SCT compared to 53 other patients who
were treated without transplantation.
Here, we report our experience in 6 patients with
BPDC treated since 2006 at our department. In line
with published data [5], we show that initial response
to acute leukemia-type chemotherapy treatment is
good, but relapse occurred very rapidly after a median
of only 7 months if alloSCT was not performed in first
remission.
The high relapse rate despite good responses
underlines the need for more effective consolidation
strategies. Given the success anecdotally seen with
myeloablative alloSCT in young patients, we decided
to offer our patients, who were all elderly, alloSCT
with dose-reduced conditioning. We show here for
the first time that RIC alloSCT may offer curative po-
tential also in elderly patients. This is of particular im-
portance because the majority of patients affected by
BPDC is beyond 60 years of age [4,5]. Although the
conditioning regimens used for patients with BPDC
in our institution were not myeloablative by the
traditional criteria, they were still rather intense,
which on the one hand may favor the conditioning
regimen to be responsible for disease control after
alloSCT. The fact that the 2 patients with active or
refractory disease achieved CR immediately after
transplantation is in keeping with this hypothesis. On
the other hand, the only long-term remission of
BPDC observed to date with RIC is our patient #1,
who received a transplant from a mismatched
1254 Biol Blood Marrow Transplant 17:1250-1254, 2011S. Dietrich et al.unrelated donor and was the only 1 in our series who
suffered from clinically significant chronic graft-
versus-host disease (cGVHD). This points to the exis-
tence of a graft versus leukemia effect (GVL) being
potentially effective in BPDC.However, the 2 patients
who were transplanted in remission and did not expe-
rience disease recurrence also received the most inten-
sive conditioning (Table 2). Further studies with larger
patient numbers are necessary for valid conclusions on
this issue.
Taken together, our data suggests that alloSCT
from matched or mismatched unrelated donors
using fludarabine-busulfan-cyclophosphamide or
fludarabine-treosulfan conditioning is feasible in el-
derly patients with BPDC, can induce responses in
relapsed and refractory disease, and can provide
long-term disease control at least in patients who un-
dergo alloSCT in remission. It remains to be settled
if the activity of the alloSCT regimens used here relies
predominantly on the cytotoxicity of conditioning, or
if there is a substantial contribution of GVL effects.
Although the numbers are small and the follow-up is
short, the quality of responses and the remission dura-
tion achieved by the alloSCT approach used here
appear to be markedly superior to that of nontrans-
plantation strategies, suggesting that alloSCT should
be pursued aggressively in patients with BPDC up to
70 years of age, preferentially within prospective clin-
ical studies.
In conclusion, it seems that broad implementation
of alloSCT into the treatment algorithm could help to
improve the otherwise fatal prognosis of BPDC even
in elderly patients representing the typical target
population of the disease. Given the fact that relapse
after first-line therapy is inevitable and taking into ac-
count the difficulties of achieving a second response,
alloSCT might be considered in eligible patients
already in first remission.ACKNOWLEDGMENTS
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